"Data from the clinical trial also showed that ATCwas especially...

"Data from the clinical trial also showed that ATC
was especially effective when used with two existing marketed HIV drugs."

HIV integrase:

Since the approval of Merck’s raltegravir (Isentress®), which targets HIV integrase, this drug has been widely
prescribed and has demonstrated itself to be a most effective therapy for HIV infections in combination with an
optimised background regimen. In 2010 Isentress® generated global revenues of around US$1Bn.

"Avexa has discovered a number of novel compound classes with activity superior to raltegravir against wild
type HIV-1. Moreover, these compounds are highly potent against raltegravir- and elvitegravir-resistant
viruses."